Patents Assigned to SomaLogic, Inc.
-
Patent number: 10648972Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art, including using a solid support, using mass spectrometry, and using quantitative polymerase chain reaction (Q-PCR).Type: GrantFiled: January 23, 2018Date of Patent: May 12, 2020Assignee: SomaLogic, Inc.Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
-
Patent number: 10634679Abstract: Modified Tryptamine, Tryptamine-2?-deoxy-uridine (TrpdU) and TrpdU-phosphoramidites for oligonucleotide synthesis are provided, as well as improved methods of their synthesis and oligonucleotides comprising at least one modified TrpdU nucleotide.Type: GrantFiled: March 13, 2017Date of Patent: April 28, 2020Assignee: SomaLogic, Inc.Inventor: John Rohloff
-
Patent number: 10620210Abstract: The present invention provides aptamers that specifically bind to the EGF receptor in a sample, and diagnostic and analytical methods using those aptamers. In some embodiments, the aptamers include a 3? cap. In some embodiments, the 3? cap is an inverted deoxythymidine. In some embodiments the aptamers include a spacer and at least one moiety selected from the group consisting of binding pair member and a detectable label, wherein the spacer is attached to the 5?-end of the aptamer and the moiety is attached the 5? end of the spacer. In some embodiments the spacer is hexaethylene glycol. In some embodiments, the binding pair member biotin. In some embodiments the detectable label is a fluorophore.Type: GrantFiled: May 5, 2017Date of Patent: April 14, 2020Assignees: Quest Diagnostics Investments Incorporated, Somalogic, Inc.Inventors: Chris Bock, Deborah Ayers, Malti P. Nikrad, Bharat Nathu Gawande, Jennifer C. Bertino, Weimin Sun, Charles M. Strom, Noh Jin Park
-
Publication number: 20200081001Abstract: Apparatus and methods for the detection of proteins in biological fluids such as urine using a label-free assay is described. Specific proteins are detected by their binding to highly specific capture reagents such as SOMAmers that are attached to the surface of a substrate. Changes to these capture reagents and their local environment upon protein binding modify the behavior of color centers (e.g., fluorescence, ionization state, spin state, etc.) embedded in the substrate beneath the bound capture reagents. These changes can be read out, for example, optically or electrically, for an individual color center or as an average response of many color centers.Type: ApplicationFiled: November 18, 2019Publication date: March 12, 2020Applicant: SomaLogic, Inc.Inventors: Jason Paul CLEVELAND, Karoly HOLCZER, Barry Patrick John VANT-HULL
-
Patent number: 10544419Abstract: Aptamers having improved stability against nucleases that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.Type: GrantFiled: May 10, 2018Date of Patent: January 28, 2020Assignee: SomaLogic Inc.Inventors: Nebojsa Janjic, Daniel W. Drolet, Amy D. Gelinas, Chi Zhang, Michael Vrkljan
-
Patent number: 10538771Abstract: Described herein are compositions and methods for detecting the presence or absence of a microorganism in a sample comprising contacting the sample with an aptamer capable of binding to a cell-surface protein of the microorganism to form a complex, contacting the mixture with a second aptamer capable of binding to the first cell-surface protein or a second cell-surface protein of the microorganism; and performing an assay to detect the second aptamer, wherein detecting the second aptamer indicates that the microorganism is present in the sample, and wherein not detecting the second aptamer indicates that the microorganism is absent from the sample.Type: GrantFiled: August 31, 2018Date of Patent: January 21, 2020Assignee: SomaLogic, Inc.Inventors: Urs A. Ochsner, Nebojsa Janjic
-
Patent number: 10526663Abstract: The present invention relates to a method of detecting a microorganism, in particular Staphylococcus aureus, in a sample, comprising the steps of a) incubating the sample with a slow off-rate modified aptamer (SOMAmer) comprising a fluorescent label, b) optionally washing the sample, c) analyzing the sample by a fluorescence-based detection method. The invention further relates to a slow off-rate modified aptamer comprising a fluorescent label, wherein the SOMAmer comprises a nucleotide sequence specific for Staphylococcus aureus, its use for detecting Staphylococcus aureus cells in a sample, and to a microarray or biosensor and a kit comprising at least one of such SOMAmers comprising a fluorescent label.Type: GrantFiled: February 20, 2015Date of Patent: January 7, 2020Assignees: Merck Patent GmbH, SOMALOGIC, Inc.Inventors: Anne Baumstummler, Frederic Marc-Kreucher, David Lehmann, Urs Ochsner, Nebojsa Janjic
-
Patent number: 10481155Abstract: Apparatus and methods for the detection of proteins in biological fluids such as urine using a label-free assay is described. Specific proteins are detected by their binding to highly specific capture reagents such as SOMAmers that are attached to the surface of a substrate. Changes to these capture reagents and their local environment upon protein binding modify the behavior of color centers (e.g., fluorescence, ionization state, spin state, etc.) embedded in the substrate beneath the bound capture reagents. These changes can be read out, for example, optically or electrically, for an individual color center or as an average response of many color centers.Type: GrantFiled: March 9, 2018Date of Patent: November 19, 2019Assignee: SomaLogic, Inc.Inventors: Jason Paul Cleveland, Karoly Holczer, Barry Patrick John Vant-Hull
-
Patent number: 10422794Abstract: The present disclosure describes methods, devices, reagents, and kits for the detection of one or more target molecules that may be present in a test sample. In one embodiment, a test sample is contacted with an aptamer that includes a tag and has a specific affinity for a target molecule. An aptamer affinity complex that includes an aptamer bound to its target molecule is allowed to form. If the test sample contains the target molecule, an aptamer affinity complex will generally form in the test sample. The aptamer affinity complex is optionally converted to an aptamer covalent complex that includes an aptamer covalently bound to its target molecule. The aptamer affinity complex (or optional aptamer covalent complex) can then be detected and/or quantified using any of a variety of methods known to one skilled in the art.Type: GrantFiled: December 12, 2014Date of Patent: September 24, 2019Assignee: SomaLogic, Inc.Inventors: James R. Heil, Daniel J. Schneider, Daniel T. Nieuwlandt, Sheri K. Wilcox, Dominic Zichi, Todd Gander, Bruce Eaton, Larry Gold
-
Publication number: 20190277842Abstract: Apparatus and methods for the detection of proteins in biological fluids such as urine using a label-free assay is described. Specific proteins are detected by their binding to highly specific capture reagents such as SOMAmers that are attached to the surface of a substrate. Changes to these capture reagents and their local environment upon protein binding modify the behavior of color centers (e.g., fluorescence, ionization state, spin state, etc.) embedded in the substrate beneath the bound capture reagents. These changes can be read out, for example, optically or electrically, for an individual color center or as an average response of many color centers.Type: ApplicationFiled: March 9, 2018Publication date: September 12, 2019Applicant: SomaLogic, Inc.Inventors: Jason Paul CLEVELAND, Karoly HOLCZER, Barry Patrick John VANT-HULL
-
Patent number: 10408847Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection, treatment and diagnosis of tuberculosis (TB). In one aspect, the present application includes the identification of biomarkers that can be used alone or in various combinations for the detection of TB, including those set forth in Tables 1, 2, 4, 5, and 8 to 12. In another aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose or prognose TB or follow treatment response. In another aspect, methods are provided for diagnosing TB in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Tables 1, 2, 4, 5, and 8 to 12, wherein the individual is classified as having TB, or the likelihood of the individual having TB is determined, based on the at least one biomarker value.Type: GrantFiled: September 20, 2017Date of Patent: September 10, 2019Assignee: SomaLogic, Inc.Inventors: Urs Ochsner, David G. Sterling, Nebojsa Janjic
-
Patent number: 10392621Abstract: Described herein are compositions comprising a first aptamer, second aptamer and a target that are capable of forming a ternary complex, and wherein the first aptamer and the second aptamer comprise C-5 pyrimidine modification schemes that are different, and methods of making and using such compositions.Type: GrantFiled: February 13, 2018Date of Patent: August 27, 2019Assignee: SomaLogic, Inc.Inventors: Urs A. Ochsner, Louis S. Green, Larry Gold, Nebojsa Janjic
-
Patent number: 10370669Abstract: Described herein are aptamers capable of binding to growth differentiation factor 8 (GDF8) protein; compositions comprising a GDF8 binding aptamer; and methods of making and using the same.Type: GrantFiled: February 5, 2016Date of Patent: August 6, 2019Assignee: SomaLogic, Inc.Inventors: Urs Ochsner, Louis Green, Nebojsa Janjic
-
Patent number: 10359435Abstract: Methods, compositions, and kits for determining whether a subject has non-alcoholic fatty liver disease (NAFLD) are provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatosis are also provided. Methods, compositions, and kits for determining whether a subject has non-alcoholic steatohepatitis (NASH) are also provided.Type: GrantFiled: March 2, 2018Date of Patent: July 23, 2019Assignee: SomaLogic, Inc.Inventors: Malti Nikrad, Stuart G. Field, Stephen Alaric Williams
-
Patent number: 10359425Abstract: The present application includes biomarkers, methods, devices, reagents, systems, and kits for the detection and diagnosis of lung cancer. In one aspect, the application provides biomarkers that can be used alone or in various combinations to diagnose lung cancer or permit the differential diagnosis of pulmonary nodules as benign or malignant. In another aspect, methods are provided for diagnosing lung cancer in an individual, where the methods include detecting, in a biological sample from an individual, at least one biomarker value corresponding to at least one biomarker selected from the group of biomarkers provided in Table 1, Col. 2, wherein the individual is classified as having lung cancer, or the likelihood of the individual having lung cancer is determined, based on the at least one biomarker value.Type: GrantFiled: September 9, 2009Date of Patent: July 23, 2019Assignee: SomaLogic, Inc.Inventors: Larry Gold, Marty Stanton, Edward N. Brody, Rachel M. Ostroff, Dominic Zichi, Alex A. E. Stewart
-
Publication number: 20190177730Abstract: Polynucleotides, such as aptamers, comprising at least first one 5-position modified pyrimidine and at least one second 5-position modified pyrimidine are provided, wherein the first and second 5-position modified pyrimidines are different. Methods of selecting and using such polynucleotides, such as aptamers, are also provided.Type: ApplicationFiled: June 30, 2017Publication date: June 13, 2019Applicant: SOMALOGIC, INC.Inventors: Jeff CARTER, Bharat GAWANDE, Nebojsa JANJIC, Daniel SCHNEIDER
-
Patent number: 10316321Abstract: The present disclosure describes improved SELEX methods for producing aptamers that are capable of binding to target molecules and improved photoSELEX methods for producing photoreactive aptamers that are capable of both binding and covalently crosslinking to target molecules. Specifically, the present disclosure describes methods for producing aptamers and photoaptamers having slower dissociation rate constants than are obtained using prior SELEX and photoSELEX methods. The disclosure further describes aptamers and photoaptamers having slower dissociation rate constants than those obtained using prior methods. In addition, the disclosure describes aptamer constructs that include a variety of functionalities, including a cleavable element, a detection element, and a capture or immobilization element.Type: GrantFiled: January 23, 2018Date of Patent: June 11, 2019Assignee: SomaLogic Inc.Inventors: Dominic Zichi, Sheri K. Wilcox, Chris Bock, Daniel J. Schneider, Bruce Eaton, Larry Gold
-
Patent number: 10239908Abstract: Described herein are 5-position modified cytosine nucleotides and nucleosides as well as phosphoramidites and triphosphates derivatives thereof. Further provided are methods of making and using the same, and compositions and uses of the modified nucleosides as part of a nucleic acid molecule (e.g., aptamer).Type: GrantFiled: March 7, 2018Date of Patent: March 26, 2019Assignee: Somalogic, Inc.Inventors: John Rohloff, Nebojsa Janjic, Bharat Nathu Gawande
-
Patent number: 10221207Abstract: The present disclosure relates to the field of nucleic acid chemistry, specifically to 5-position modified uridines as well as phosphoramidite and triphosphate derivatives thereof. The present disclosure also relates to methods of making and using the same.Type: GrantFiled: July 14, 2017Date of Patent: March 5, 2019Assignee: SomaLogic, Inc.Inventors: John Rohloff, Nebojsa Janjic, Jeffrey D. Carter, Catherine Fowler
-
Patent number: 10221421Abstract: Aptamers that bind PDGF and aptamers that bind VEGF are provided. In addition, aptamer constructs comprising a PDGF aptamer and a VEGF aptamer are provided. Pharmaceutical compositions comprising the aptamers and aptamer constructs are provided, as well as methods of treating conditions using the aptamers and aptamer constructs.Type: GrantFiled: May 23, 2017Date of Patent: March 5, 2019Assignee: Somalogic, Inc.Inventors: Thale C. Jarvis, John C. Rohloff, Amy D. Gelinas, Chi Zhang, Daniel W. Drolet, Sheela M. Waugh, Nebojsa Janjic